Zusammenfassung
Paul Ehrlich gehörte zu den ersten, die konsequent darauf hingewiesen haben, daß es notwendig sei, Substanzen mit selektiver Toxizität zu entdecken, um eine erfolgreiche Chemotherapie mikrobiell verursachter Erkrankungen durchführen zu können. Es gilt also Unterschiede im Stoffwechsel von Mikro- und Makroorganis-men auszunutzen, um die Krankheitserreger maximal zu schädigen und den Wirtsorganismus zu schonen. In den meisten Fällen führten Zufälle auf die Spuren derartiger Wirkprinzipien. Dies gilt auch für die Azol-Antimykotika.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Bozzette SA, Larsen RA, Chiu J, Leal MAE, JacobsenJ, Rothman P, Robinson P, Gilbert G, McCutchan JA, Tilles J, Leedom JM, Richman DD and the California treatment group (1991) A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. N Engl J Med 324:580–584
Brammer KW, Farrow PR, Faulkner JK (1990) Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 12 (Suppl 1):S318-S326
Conney AH (1986) Induction of microsomal cytochrome P-450 enzymes: The first Bernhard B. Brodie lecture at Pennsylvannia State University. Life Sci 39:2493–2518
Daneshmend TK, Warnock DW (1988) Clinical pharmocokinetics of ketoconazole. Clin Pharma-cokin 14:13–34
Daneshmend TK, Warnock DW, Ene MD, Johnson EM, Potten MR, Richardson MD, Williamson PJ (1984) Influence of food on the pharmacokinetics of ketoconazole. Antimicrob Agents Chemother 25:1–3
Denning DW, Follansbee SE, Scolaro M, Norris S, Edelstein H, Stevens DA (1991) Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med 324:654–662
Drouhet E, Dupont B (1987) Evolution of antifungal agents: past, present, and future. Rev Infect Dis 9 (Suppl 1):S4-S14
Galgiani JN (1990) Suscetibility of Candida albicans and other yeasts to fluconazole: relation between in vitro and in vivo studies. Rev Inf Dis 12 (Suppl 3):S272-S275
Grant SM, Clissold SP (1989) Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 37:310–344
Grant SM, Clissold SP (1990) Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 39:877–916
Hardin TC, Graybill JR, Fetchick R, Woestenborghs R, Rinaldi MG, Kuhn JG (1988) Pharmacokinetics of intraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 32:1310–1313
Lazar JD, Wilner KD (1990) Drug interactions with fluconazole. Rev Infect Dis 12 (Suppl 1): S 327–S333
Nebert DW, Go’nzalez FJ (1987) P-450 genes: structure, evolution, and regulation. Ann Rev Biochem 56:945–993
Nebert DW, Nelson DR, Coon MJ, Estabrook RW, Feyereisen R, Fujii-Kuriyama Y, Gonzalez FJ, Guengerich FP, Gunsalus IC, Johnson EJ, Loper JC, Sato R, Waterman MR, Waxman DJ (1991) The P450 gene superfamily: Update on new sequences, gene mapping, and recommended nomenclature. DNA 10:1–14
Pont A, Graybill JR, Craven PC, Galgiani JN, Dismuks WE, Reitz RE, Stevens DA (1984) High-dose ketoconazole therapy and adrenal and testicular function in humans. Arch Intern Med 144:2150–2153
Pont A, Goldman ES, Sugar AM, Siiteri PK, Stevens DA (1985) Ketoconazole-induced increase in estradiol-testosterone ratio. Probable explanation for gynecomastia. Arch Intern Med 145:1429–1431
Richardson K, Cooper K, Marriott MS, Tarbit MH, Troke PF, Whittle PJ (1990) Discovery of fluconazole, a novel antifungal agent. Rev Inf Dis 12 (Suppl 3):S267-S271
Rodrigues AD, Waddell PR, Ah Sing E, Morris BA, Wolf CR, Ioannides C (1988) Induction of the rat hepatic microsomal mixed-function oxidases by 3 imidazole-containing antifungal agents: Selectivity for the cytochrome P450 IIB and P450III families of cytochromes P450. Toxicol 50:283–301
Saag MS, Dismukes WE (1988) Azole antifungal agent: Emphasis on new triazoles. Antimicrob Agents Chemother 32:1–8
Shepherd FA, Hofert B, Evans WK, Emery G, Trachtenberg J (1985) Ketoconazole. Use in the treatment of ectopic adrenocorticotropic hormone production and Cushing’s syndrome in small-cell lung cancer. Arch Intern Med 145:863–864
Sugar AM, Stern JJ, Dupont B (1990) Overview: treatment of cryptococcal meningitis. Rev Infect Dis 12(Suppl 3):S338-S348
Tarbit MH (1990) Pharmacokinetic aspects of antifungal therapy. In: Ryley JF (Ed) Chemotherapy of fungal diseases, Springer, Berlin Heidelberg New York, pp 183–204
Thorpe JE, Baker N, Bromett-Petit M (1990) Effect of oral antacid administration on the pharmacokinetics of oral fluconazole. Antimicrob Agents Chemother 34:2032–2033
Trenk D, Brett W, Jähnchen E, Birnbaum D (1987) Time course of cyclosporine/itraconazol interaction. Lancet 11:1335–1336
Tricot G, Joosten E, Boogaerts MA, Vande Pitte J, Cauwenbergh G (1987) Ketoconazole versus Itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: Preliminary results of two non-randomized studies. Rev Infect Dis 9 (Suppl 1):S94-S99
Troke PF, Andrews RJ, Pye GW, Richardson K (1990) Fluconazole and other azoles: translation of in vitro activity to in vivo and clinical efficacy. Rev Inf Dis 12 (Suppl 3):S276-S280
Van Cauteren H, Heykants J, de Coster R, Cauwenbergh G (1987) Itraconazole: pharmacologic studies in animals and humans. Rev Inf Dis 9 (Suppl 1):S43-S46
Vanden Bossche H (1985) Biochemical targets for antifungal azole derivatives: hypothesis on the mode of action. Curr Top Med Mycol 1:313–351
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Stahlmann, R., Schulz-Schalge, T., Lode, H. (1991). Wirkungsweise und Pharmakokinetik neuerer Azol-Antimykotika. In: Staib, F., Huhn, D. (eds) Pilzinfektionen bei abwehrgeschwächten Patienten. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76845-3_9
Download citation
DOI: https://doi.org/10.1007/978-3-642-76845-3_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-54391-6
Online ISBN: 978-3-642-76845-3
eBook Packages: Springer Book Archive